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Background. Vagus nerve stimulation (VNS) therapy is associated with a decrease in seizure frequency in partial-onset
seizure patients. Initial trials suggest that it may be an eﬀective treatment, with few side-eﬀects, for intractable
depression.
Method. An open, uncontrolled European multi-centre study (D03) of VNS therapy was conducted, in addition to
stable pharmacotherapy, in 74 patients with treatment-resistant depression (TRD). Treatment remained unchanged for
the ﬁrst 3 months ; in the subsequent 9 months, medications and VNS dosing parameters were altered as indicated
clinically.
Results. The baseline 28-itemHamilton Depression Rating Scale (HAMD-28) score averaged 34. After 3 months of VNS,
response rates (o50% reduction in baseline scores) reached 37% and remission rates (HAMD-28 score <10) 17%.
Response rates increased to 53% after 1 year of VNS, and remission rates reached 33%. Response was deﬁned as
sustained if no relapse occurred during the ﬁrst year of VNS after response onset ; 44% of patients met these criteria.
Median time to response was 9 months. Most frequent side-eﬀects were voice alteration (63% at 3 months of stimu-
lation) and coughing (23%).
Conclusions. VNS therapy was eﬀective in reducing severity of depression; eﬃcacy increased over time. Eﬃcacy
ratings were in the same range as those previously reported from a USA study using a similar protocol ; at 12 months,
reduction of symptom severity was signiﬁcantly higher in the European sample. This might be explained by a small but
signiﬁcant diﬀerence in the baseline HAMD-28 score and the lower number of treatments in the current episode in the
European study.
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Introduction
Antidepressant drugs, which are associated with
modulation of monoaminergic neurotransmission
and/or regulation of the hypothalamic–pituitary–
adrenal axis (Mason & Pariante, 2006), are eﬀective
in improving depressive symptoms in major de-
pression (Mann, 2005). These medications, in con-
junction with certain methods of psychotherapy
and electroconvulsive therapy (ECT), are eﬀective
at alleviating depressive symptomatology in most
patients (Andrews & Nemeroﬀ, 1994 ; Mann, 2005).
However, these treatments do not work for all
patients. Keller et al. (1992) studied the course of de-
pression treatment prospectively over a 5-year period
and found that the recovery rate decreased over time.
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Their ﬁndings of 9.3% (40/431 patients) at the 5-year
point supported earlier longitudinal research that
found 6–13% of patients remained on a course of
chronic unremitting depression despite adequate
treatment. A more recent study found that 63.2%
of patients included in the STAR-D study were not
treated to remission during the acute study phase
(Rush et al. 2006). Patients who do not respond to
known treatment combinations including ECT are
thus referred to as suﬀering from treatment-resistant
depression (TRD).
A need for the development of alternative treat-
ments for TRD that are eﬀective, have fewer side-
eﬀects or have longer-lasting antidepressant eﬀects
has been identiﬁed (Nestler, 1998 ; Schlaepfer &
Kosel, 2004). Vagus nerve stimulation (VNS) therapy
is a type of treatment where a small electrical pulse is
administered through an implanted neurostimulator
to a bipolar lead attached to the left vagus nerve
(George et al. 2000 ; Kosel & Schlaepfer, 2003 ;
Schlaepfer & Kosel, 2004). This procedure has been
studied in patients with treatment-resistant epilepsy
and has been demonstrated to be eﬀective in reducing
seizure frequency (Ben-Menachem et al. 1994; The
Vagus Nerve Stimulation Study Group, 1995 ; Hand-
forth et al. 1998 ; Morris & Mueller, 1999 ; Uthman,
2000 ; Ben-Menachem, 2001; Schachter, 2002). Signiﬁ-
cant and clinically meaningful antidepressant eﬀects
of VNS in epilepsy patients have been described, in-
dependent of reduction of seizure frequency (Elger
et al. 2000 ; Harden et al. 2000 ; Helmstaedter et al. 2001).
The precise mechanism by which VNS might inﬂu-
ence depressive symptoms is not known, but VNS
clearly has eﬀects on brain function (Kosel &
Schlaepfer, 2002 ; Groves & Brown, 2005). Preliminary
evidence for the mode of action of the putative anti-
depressant eﬀect was obtained from brain imaging
studies indicating that VNS aﬀects the metabolism
of limbic structures relevant to mood regulation
(Henry et al. 1999). VNS has been shown to induce
c-fos immunolabelling in several forebrain structures,
including the posterior cortical amygdaloid nucleus,
cingulate and retrosplenial cortex, ventromedial and
arcuate hypothalamic nuclei (Naritoku et al. 1995).
Another potential mechanism of action, supported by
both animal and human studies, might be that VNS
inﬂuences monoaminergic neurotransmission. Unlike
other antidepressants, VNS seems not to be associated
with an initial reduction in the ﬁring rates of
serotonergic neurones ; in an animal study, raphe
neurone ﬁring rates increased progressively over 2
weeks, which could be an explanation for the slow
and progressive increase of antidepressant response
in clinical VNS studies (Dorr & Debonnel, 2006).
In a clinical VNS study, no signiﬁcant change
in cerebrospinal ﬂuid (CSF) metabolites of norepine-
phrine (NE) and serotonin (5-HT) was seen in patients
treated for 3 months compared with pretreatment
levels while concentrations of homovanilinic acid
in the CSF were increased signiﬁcantly in treated
patients compared to those treated with sham only
(Carpenter et al. 2004). Reviews on the emerging
body of functional neuroimaging [positron emission
tomography (PET), single photon emission computed
tomography (SPECT), and functional magnetic reson-
ance imaging (fMRI)] eﬀects of VNS have found the
data diﬃcult to reconcile, mainly because of the small
sample sizes, diﬀerent diagnoses, diﬀerent types of
concomitant antidepressant therapies and diﬀerent
time-point of scans obtained (Chae et al. 2003;
Nemeroﬀ et al. 2006).
A SPECT study in 12 patients with TRD found that
after 4 weeks of VNS treatment, blood ﬂow had
decreased in the amygdala ; hippocampus; thalamus;
putamen; caudate ; brainstem; subgenual, ventral an-
terior, posterior and dorsal anterior cingulate cortex ;
and orbito-, ventro- and dorsolateral prefrontal cortex.
The only area of increased ﬂow was found in the
middle frontal gyrus (Zobel et al. 2005). In a 15O-PET
study of four patients with VNS for 3 weeks, patients
were scanned four times in an ‘oﬀ–on’ design. Blood
ﬂow increases were found in the orbitofrontal cortex,
dorsal and ventral anterior cingulate ; superior and
inferior frontal gyri ; cerebellum; and putamen; while
decreases were found in temporal and parietal cortex
(Conway et al. 2006).
Several studies assessing antidepressant properties
of VNS in TRD have been conducted. The ﬁrst open,
unblinded four-centre pilot study (D01) of 60 patients
showed eﬃcacy in very treatment-resistant patients, of
whom 30.5% met criteria for response after 3 months
of VNS (Rush et al. 2000). The authors found that
the number of unsuccessful adequate antidepressant
treatment trials, rated by the Antidepressant Treat-
ment History Form (ATHF; Prudic et al. 1990), during
the current episode was inversely correlated with VNS
response. The response rate was 50% in patients
with two to three failed trials in the current episode,
29.1% after four to seven failed trials, and 0%
after more than seven failed trials (Sackeim et al.
2001). The authors concluded that VNS is most
eﬀective in patients with moderate but not extreme
levels of resistance to conventional antidepressant
treatments.
A subsequent sham-controlled, multisite, double-
blind trial (D02) in a larger sample did not demon-
strate superiority of active VNS treatment over sham
treatment after 3 months. In the active VNS group
(n=112), 15.2% of the patients met criteria for re-
sponse versus 10.0% in the sham group (Rush et al.
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2005a), despite excluding patients with more than
six adequate antidepressant medication trials (as
measured by the ATHF; Prudic et al. 1990). The
authors suggested that the lack of superiority of active
versus sham treatment could have been due to lower
stimulation current. While in the ﬁrst 3 months of
VNS therapy output current in the D01 study ranged
from 0.25 to 3.00 mA (mean 0.96¡0.54 mA) (Sackeim
et al. 2001), in the D02 study output current ranged
from 0.25 to 3.00 mA (mean 0.67¡0.33 mA) (Rush
et al. 2005a). Longer-term outcomes following the
ﬁrst 3 months of VNS in the D02 study revealed that
at 1 year of VNS therapy, 29.8% had responded and
17.1% had remitted (mean output current 1.0 mA,
range 0–2 mA).
The results of 1 year of VNS in the D02 study
were signiﬁcantly superior to outcomes at 1 year in a
cluster-matched but more randomized comparison
sample of patients receiving treatment as usual (TAU)
(George et al. 2005). Response rates as measured
by the 24-item Hamilton Depression Rating Scale
(HAMD-24) were 29.8% (D02) and 12.5% (TAU,
n=104) at 1 year. This TAU sample was acquired
initially to deﬁne prospectively the outcome of
TAU on such patients. In both the long-term TAU
and VNS samples, medications and psychotherapy
could be added or dropped and doses could be
changed, and other non-pharmacological treatments
[ECT, transcranial magnetic stimulation (TMS), light
therapy] could be used. A careful examination of the
potential contributions to the diﬀerential outcomes in
these two samples failed to reveal that any baseline
covariate, intercurrent treatment or medication man-
agement diﬀerences could account for the diﬀerence in
outcome. In summary, results of open-label, uncon-
trolled trials examining eﬃcacy of VNS in treatment-
resistant major depression seem to point to both acute
and longer-term eﬀectiveness.
The European study of VNS for TRD reported
here (D03) was conducted to determine if the USA
results could be replicated using a similar study
protocol in a diﬀerent patient population with diﬀer-
ent severity and in a diﬀerent health-care environ-
ment. We report on the acute and medium-term
outcome after 3 and 12 months in a European patient
sample.
Method
Protocols
Patients with treatment-resistant major depression
participating in the D03 study were enrolled from
2001 to 2005 in six European countries (Belgium,
Germany, Ireland, Sweden, Switzerland, the UK) in an
uncontrolled open-label study design. This protocol
was very similar to the D01 study conducted in the
USA, except that (1) study inclusion required a score
o20 on the HAMD-24 (Hamilton, 1967) in the D03
study, as opposed to o20 on the 28-item HAMD
(HAMD-28) in the D01 study, (2) the maximum age at
entry was 80 in the D03 study and 70 in the D01 study,
and (3) the number of failed adequate medication
trials waso2 but<6 in the D03 study versuso2 in the
D01 study.
Patients
Patients suﬀered from non-psychotic major depressive
disorder (MDD) or bipolar I or II disorder (according
to DSM-IV diagnosis). The current major depressive
episode (MDE) had lasted more than 2 years and/or
the patient had had more than four lifetime MDEs. At
study entry the patients ranged in age from 18 to 80
years. Pregnant women and those not using generally
accepted methods of birth control were excluded.
Patients had to have experienced inadequate anti-
depressant response with 2–6 treatments during the
current MDE. Treatment adequacy was rated with
the Antidepressant Treatment History Form (ATHF),
an adequate trial resulted in an Antidepressant
Resistance Rating (ARR) score of o3 (Prudic et al.
1990). Patients with bipolar disorder had to be either
treatment resistant to, intolerant to, or have a medical
contraindication to, lithium. All patients had to have
had at least 6 weeks of psychotherapy (during any
MDE) that resulted in inadequate clinical improve-
ment.
Patients with atypical or psychotic depression
were excluded, as were patients with a history of
schizophrenia, schizo-aﬀective disorder or delusional
disorder, bipolar disorder with rapid cycling and
patients with a secondary diagnosis of delirium,
dementia, amnesic or other cognitive disorder.
Patients with clinically signiﬁcant, current suicidal
ideation and those with health risks related to the
surgical procedures and stimulation were also ex-
cluded.
Study overview
The study was an open, unblinded, not sham con-
trolled, multi-centre trial conducted at nine European
sites. The ethics committee at each study site approved
the study protocol. After written informed consent
was obtained, patients completed a baseline period
(up to 4 weeks) before undergoing device implan-
tation. Patients were assessed at two study visits
during this period. Only patients with a score of 20
or higher on the HAMD-24 at both visits were im-
planted. After implantation, a 2-week single-blinded
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recovery period followed. Patients were told ‘stimu-
lation may or may not be turned on immediately after
implantation’. Stimulation was initiated if patients
scored 18 or more on the HAMD-24 at the end of
the recovery period. During the following 2-week
stimulation adjustment period, stimulation was in-
creased individually to the maximal, comfortably
tolerated level. Stimulation parameters were then set
and remained ﬁxed for the following 8 weeks of the
acute study period. During the acute study period,
clinic visits were held at weeks 1, 2, 3, 4, 6 and 8.
Following the acute study period (3 months after
implantation), patients entered the long-term follow-
up period. If patients met criteria for response at the
end of the acute study period (reduction of o50% of
the baseline HAMD-24 score), monthly visits followed
for the remaining 9 months ; if they did not meet
the response criteria, quarterly visits followed for the
remaining 9 months. During the long-term follow-
up period, changes in stimulation parameters and
medications were permitted.
VNS therapy: implantation and treatment
Implantation and treatment parameters used in this
study were identical to those used in epilepsy studies
(Ben-Menachem et al. 1994 ; Handforth et al. 1998).
The VNS therapy system (Cyberonics Inc., Houston,
TX, USA) consisted basically of three parts : (1) the
implantable, multi-programmable bipolar pulse gen-
erator, which is similar to a cardiac pacemaker in its
size and shape; (2) two helicoidal electrodes that are
wrapped around the vagus nerve and are linked to
the pulse generator by a bipolar lead; and (3) a pro-
gramming wand linked to a computer running a
programming software, which allows non-invasive
programming, functional assessment (device diag-
nostics) and data retrieval. The pulse generator is
implanted in a subcutaneous pocket in the left chest
wall and the electrodes are attached to the vagus
nerve. The electrodes are connected to the stimulator
through a subcutaneous tunnel. After the recovery
period, stimulation was initiated at the following
parameters : current intensity of 0.25 mA, pulse fre-
quency of 20 Hz, pulse width of 500 ms with stimu-
lation on for 30 s and oﬀ for 5 min. The output current
was then (during the stimulation adjustment period)
increased in 0.25 mA, increments until an individual
maximal tolerable and comfortable level was reached.
At each study visit, the accuracy of the stimulation
parameters was veriﬁed.
Concomitant therapy
Concomitant treatment with antidepressant medi-
cations (antidepressants, mood stabilizers or other
psychotropic medications) was permitted, but it had
to be stable for 4 weeks prior to study entry (baseline),
during the recovery period and the acute study phase
(i.e. for the ﬁrst 12 weeks following implantation).
Thereafter, treatments could be added, adjusted or
stopped. Investigational drugs and treatment with
another investigational device were not permitted.
Other non-psychiatric medications (e.g. antibiotics,
analgesics) were allowed and were recorded at each
visit.
Evaluation/outcome measures
Outcome parameters. Baseline depression severity
(HAMD-24 score at baseline) was compared to ratings
2 weeks after implantation (end of recovery period) ;
after 3 months of VNS (end of acute study period) ; and
after an additional 3, 6 and 9 months (end of long-term
study period).
Primary clinical outcome. Response was deﬁned as a
o50% reduction in HAMD-24 score from the baseline
period (mean of visits 1 and 2), remission was deﬁned
as a HAMD-24 scoref10.
Secondary clinical outcome parameters. Secondary out-
comes were assessed on the Montgomery–Asberg
Depression Rating Scale (MADRS) and the Inventory
of Depressive Symptomatology Self-Rated (IDS-SR).
Adverse events (AEs)
AEs events were collected by the COSTART (Coding
System for Thesaurus of Adverse Reaction Terms)
(FDA, 1995). AEs were deﬁned as events occurring on
or after the date of implantation, events not reported
as signs or symptoms at baseline and/or worsening in
severity or frequency. Presence of mania was moni-
tored using the Young Mania Rating Scale (YMRS) ; a
score of o15 was used as threshold for the diagnosis
of mania.
Statistical analysis
Baseline demographic and clinical characteristics
of the D03 and D01 patients were compared by
using the t test or the Wilcoxon rank sum test for
continuous measures, and x2 or Fisher’s exact tests
for categorical measures. Changes in HAMD scores
were analysed with repeated-measures analysis of
variance [SPSS repeated generalized linear model
(repGLM)]. Analyses are based on observed cases
(OCs) and last observation carried forward (LOCF), as
indicated. Multiple comparisons were corrected using
the Bonferroni method.
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Results
Enrolment
A total of 84 patients were eligible for inclusion in the
study and gave their signed informed consent. Ten
patients withdrew consent before implantation. Of the
74 implanted patients, four withdrew consent and
discontinued study participation during the acute
study period. Seven patients dropped out during
the ﬁrst-year long-term study period, ﬁve of them
withdrew consent due to AEs or lack of eﬃcacy (two
were explanted), and two patients committed suicide.
Demographic and baseline characteristic data for
all 74 implanted patients were analysed; outcome
data for 70 acute study period completers were avail-
able. Long-term data for 61 patients (6 months), 55
patients (9 months) and 60 patients (1 year) were
available. Various assessments are missing because
of not-conducted visits. Baseline characteristics of
both D01 and D03 patient populations are summar-
ized in Table 1. This table shows that unsuccessful
mood disorder treatments during the current MDE
averaged 6.2¡3.1. Of these, 4¡2.4 were classic anti-
depressant treatments, whereas 3.5¡1.3 trails met
ATHF criteria for adequacy. During the current epi-
sode, 38% (28/74) of patients had received ECT. The
baseline scores of depression scales (HAMD-24,
MADRS, IDS-SR) are consistent with a severe level
of depression.
Stimulation parameters
Most patients (86%) were stimulated with a 20 Hz
frequency and a 500 ms pulse width for 30 s on and
5 min oﬀ. The others diﬀered in the following par-
ameter settings : one patient had a frequency of 30 Hz
and a pulse width of 500 ms, seven patients had a fre-
quency of 20 Hz and a pulse width of 250 ms, and one
patient each had a frequency of 15 Hz and 10 Hz and
a pulse width of 250 ms ; usually parameters were
changed to increase tolerability. The output currents
ranged from 0.25 to 2 mA, (mean 1.2¡0.34 mA,
median 1.25 mA). During the long-term follow-up
period the median output current was 1.25 mA, (range
0.25–2.25 mA).
Eﬃcacy
Primary clinical outcome measures
The severity of depression as measured by the
HAMD-24 diminished signiﬁcantly after 3, 6, 9 and
12 months of VNS compared to baseline severity of
depression [repGLM, F(4)=30.028, p=0.000]. Analysis
under LOCF conditions demonstrated that the de-
crease in the severity of depression at every time-point
was signiﬁcant [repGLM, F(4)=30.718, p=0.000]. The
percentage of the patient population reaching the
response criterion was 36% (25/70) after 3 months,
increasing to 44% after 6 months (27/61), 53% (29/55)
after 9 months and 55% (33/60) after 1 year of VNS.
Under LOCF conditions, rates of response reached
34% (25/74) after 3 months, 39% (29/74) after 6
months, 46% (34/74) after 9 months and 47% (35/74)
after 1 year of VNS.
Secondary clinical outcome measures, MADRS and
IDS-SR
Reduction in severity of depression measured by
MADRS and the IDS-SR was also signiﬁcant. Decrease
in the MADRS score reached signiﬁcance at every key
outcome point compared to baseline score in both
samples [repGLM, F(4)=34.613, p=0.000]. The score
on the self-rating questionnaire (IDS-SR) also de-
creased signiﬁcantly [repGLM, F(4)=23.256, p=0.000]
and steadily over time. The mean percentage of de-
crease reached 41% after 1 year.
Comparison of results of D01 and D03 study
Depression severity rating : HAMD-28
Primary outcome measure in the D03 study was
HAMD-24, but HAMD-28 has also been assessed
and is used here for comparison. The severity of de-
pression as measured by the HAMD-28 diminished
signiﬁcantly under VNS (Fig. 1) The decreases after 3,
6, 9 and 12 months compared to baseline score reached
signiﬁcance in both samples [D03 repGLM, F(4)=
37.880, p=0.000 ; D01 repGLM, F(4)=31.255, p=0.000,
observed cases]. Analysis under LOCF conditions
conﬁrmed these results [D03 repGLM, F(4)=41.628,
p=0.000 ; D01 repGLM, F(4)=36.455, p=0.000]. The
decrease was larger in the D03 sample but the diﬀer-
ences did not reach signiﬁcance at any time-point.
Rates of response and remission
Figure 2 shows rates of response and remission in the
ﬁrst year of VNS therapy. Response was deﬁned as a
reduction ofo50% in the HAMD-28 score, remission
as a HAMD-28 score <10. Response and remission
rate increased steadily over time in both samples ; re-
sponse rate reached 53% after 12 months ; remission
rate reached 33%.
Pattern of response analysis
In order to evaluate characteristics of response during
the ﬁrst year of VNS, the sample was assigned to four
groups regarding onset and proceed of response :
(1) no response, (2) ﬂuctuating response, (3) early
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https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0033291707001924
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 17:02:16, subject to the Cambridge Core terms of use, available at
Table 1. Demographic and clinical characteristics of the D03 and D01 samples
D03
(n=74)
D01
(n=60) p
Age at implant (years) 47.4¡11.7 46.8¡8.7 0.719b
Gender, female 50 (67.6) 39 (65) 0.754a
DSM-IV diagnosis
Unipolar, recurrent 41 (55.4) 28 (47) 0.009a
Unipolar, single episode 13 (17.5) 16 (27)
Bipolar I 9 (12.2) 6 (10)
Bipolar II 11 (14.9) 10 (17)
Total unipolar 54 (73) 44 (73) 0.963a
Total length of aﬀective disorder (years) 18.54¡9.9 18.1¡10.9 0.811b
Length of current episode (years ) 3.46¡6.25 9.9¡10.8 0.000b
Number of depressive episodes lifetime
0–2 17 (23) 35 (58) 0.000a
3–5 20 (27) 18 (30)
6–10 19 (2628) 3 (5)
>10 16 (2124) 4 (7)
Unknown 2 (3) –
Total mood disorder treatments 6.2¡3.1 15.7¡7.9 0.000b
Antidepressants 4¡2.4 8.6¡4.0 0.000b
Other mood disorder treatments 1.6¡1.4 4.8¡3.5 0.000b
Anxiolytics 0.7¡0.8 1.9¡1.4 0.000b
Neuroleptics 0.0¡0.0 0.5¡0.9 0.000b
ATHF adequacy rating
Unsuccessful adequate medication trials in
the current major depressive episode
3.5¡1.3 4.8¡2.7 0.000a
ECT in current episode 28 (38) 34 (57) 0.030a
ECT lifetime 37 (50) 40 (67) 0.052a
HAMD-24 28.6¡5.3 – –
HAMD-28 34.0¡5.8 36.8¡5.8 0.006b
MADRS 32.9¡6.4 33.4¡5.7 0.635b
IDS-SR 47.3¡9.6 – –
ATHF, Antidepressant Treatment History Form; ECT, electroconvulsive therapy;
HAMD, Hamilton Depression Rating Scale ; MADRS, Montgomery–Asberg
Depression Rating Scale ; IDS-SR, Inventory of Depressive Symptomatology
Self-Rated; S.D., standard deviation.
Values are given as n (%) or mean¡ S.D.
Values in bold indicate statistical signiﬁcant diﬀerences between studies.
Samples were comparable on most baseline characteristics ; there was no diﬀerence
in age, gender and lifetime psychiatric illness. In terms of number of prior episodes,
duration of current episode and overall number of mood disorder treatments in the
current episode, the patient populations were diﬀerent. In addition, the number of
adequate antidepressant trials and the number of patients receiving ECT in the
current episode were signiﬁcantly higher in the D01 sample [x2(1)=4.725, p=0.030].
Baseline scores of depression scales (HAMD, MADRS, IDS-SR) indicated a severe
level of depressive symptoms in both samples. The diﬀerence in the baseline
HAMD-28 score between the two samples reached signiﬁcance [ANOVA,
F(1)=7.805, p=0.006] but not the diﬀerence in baseline MADRS score
[ANOVA, F(1)=0.226, p=0.635]. The scores of the IDS-SR are only available for the
D03 sample.
a x2 test.
b ANOVA F.
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response and (4) late response. Patients in the ‘no re-
sponse’ group did not meet criteria for response at any
key outcome point, in the ‘ﬂuctuating response’ group
patients met criteria for response only once or twice
but relapsed, in the ‘early response’ group patients
met criteria for response after 3 months of VNS ther-
apy and remained responders for the rest of the year,
and in the ‘late response’ group patients met criteria
for response after 6 or 9 months and remained re-
sponders for the rest of the year. Patients in the early
and late response group can therefore be counted
among sustained responders. In the D03 sample only
1-year completers were considered (n=59). The per-
centage of sustained responders is higher in the D03
sample, with 44% of the patients in the D03 sample
showing a sustained response compared to 32% in the
D01 sample. The percentages of patients with a ﬂuc-
tuating response were almost equal (32% in the D03
and 36% in the D01), but the percentage of patients
never meeting criteria for response in the ﬁrst year
was 24% in the D03 sample compared to 32% in the
D01 sample.
Adverse events (AEs)
Table 2 summarizes the rates of AEs during the ﬁrst
year of VNS and displays them in comparison to
published safety data from the D02 pivotal studies
on VNS in depression (Rush et al. 2005b). The most
common side-eﬀects in the acute study period were
voice alteration (63%), cough (26%), pain (20%) and
dyspnoea (10%). After 1 year of stimulation the most
common side-eﬀects were voice alteration (55%) and
dyspnoea (10%). The side-eﬀects were typically re-
stricted to the time of stimulation, and mild side-
eﬀects were classiﬁed as moderate diminished typi-
cally over time. No patient discontinued study partici-
pation due to AEs. During the ﬁrst year, nine patients
withdrew consent, four during the acute study period
and seven during the long-term study period (two of
them were explanted due to lack of eﬀectiveness).
There were 15 serious AEs reported during the ﬁrst
year of VNS, resulting in hospitalizations : seven epi-
sodes of worsening of depression, two committed
suicides, one brain haemorrhage due to suicide at-
tempt, one episode of nephrolithiasis, one of chole-
lithiasis, one of pulmonary embolism, one of mania
and one of syncope. Of these 15 serious AEs, only
manic episodes were judged by the investigator as
being possibly related to stimulation.
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Fig. 2. Response and remission rates (%) in the D03 (%) and
D01 (&) samples, observed cases. Response was deﬁned as
reduction ofo50% in the 28-item Hamilton Depression
Rating Scale (HAMD-28) score compared to baseline HAMD-
28 score ; remission was deﬁned as a HAMD-28 score of
f10%. Rates of both response and remission in the D03
sample exceeded rates in the D01 sample, although
diﬀerences did not reach statistical signiﬁcance.
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Fig. 1.Mean scores on the 28-item Hamilton Depression
Rating Scale (HAMD-28) at study visits for the D03 (– –%– –)
and the D01 (—#—) study. Severity of depression as
assessed by the HAMD-28 score diminished signiﬁcantly
under vagus nerve stimulation (VNS) : the decreases after 3, 6,
9 and 12 months compared to the baseline (x1 month) score
reached signiﬁcance in both study samples. The decrease was
signiﬁcantly larger after 1 year of VNS.
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Discussion
In this study we report on eﬀectiveness data of the
European (D03) multi-centre VNS study, and compare
them to the eﬀectiveness data of the USA (D01)
(Rush et al. 2000) study. Both studies were similar
in protocol design and size, but patient samples
were diﬀerent regarding baseline characteristics, for
example the proportion of bipolar I and II diagnoses,
length of current episode, number of current episodes,
total of mood disorder treatments, degree of treatment
resistance, baseline depression scores and number of
previous ECT treatments. In both studies repeated
ANOVA showed signiﬁcant reduction in severity of
depression (as measured by HAMD-24, HAMD-28
and MADRS) over time. The reduction was larger in
the European sample : response rates reached 37%
after 3 months and increased to 53% after 1 year of
VNS therapy. Remission rates reached 17% after
3 months and increased to 33% after 1 year of VNS
therapy. Rates of response and remission in the
European sample increased steadily over time, as in
the published D01 results. In our study, 44% of the
patients showed sustained response, deﬁned by the
absence of relapse after onset of response during
the ﬁrst year of VNS. The higher eﬃcacy in this study
compared to the previously published one can prob-
ably be attributed to the lower measures of baseline
depressivity.
A major shortcoming of this study, as for the USA
(D01) study, is the fact that eﬀectiveness was not as-
sessed in a sham controlled design, limiting inter-
pretations on clinical utility. It has been argued that a
controlled design would be unethical, because eligible
patients would be too depressed to be taken oﬀ
their medications and given only sham stimulation
(Shuchman, 2007). While this is correct in principle, it
would certainly be scientiﬁcally important to plan
Table 2. Adverse events recorded in the D03 study compared to published USA data (Rush et al. 2005b)
3 months 6 months 9 months 12 months
D03 USA D03 USA D03 USA D03 USA
Adverse events (n=70) (n=232) (n=61) (n=225) (n=54) (n=218) (n=60) (n=209)
Suicide attempts – 1 1 1 – 1 – 1
Suicide – – 2 – – – – –
Voice alteration 63 58 2 60 2 57 2 54
Worsening depression 1 5 – 7 2 5 – 6
Cough increased 26 24 3 9 2 7 3 6
Dyspnoea 10 14 5 16 8 15 10 16
Pain 20 6 – 6 5 5 – 6
Pharyngitis 6 6 3 4 2 4 3 5
Headache 3 5 2 4 2 4 2 4
Device site pain 4 N.A. – N.A. – N.A. – N.A.
Pain neck 7 N.A. 3 N.A. – N.A. – N.A.
Pain ear 7 N.A. 2 N.A. – N.A. – N.A.
Neuralgia 3 N.A. 56 N.A. 54 N.A. 55 N.A.
Twitching 1 N.A. – N.A. – N.A. – N.A.
Manic reaction 1 1 – <1 – – 2 –
Paresthesia 1 11 – 7 2 3 – 4
Dyspepsia 1 N.A. 2 N.A. 2 N.A. 2 N.A.
Dysphagia 6 13 – 8 – 7 2 4
Reﬂux 1 N.A. 2 N.A. – N.A. – N.A.
Gingivitis 1 N.A. – N.A. – N.A. – N.A.
Nausea 1 6 2 2 – 2 2 2
Laryngitis – N.A. 1 N.A. – N.A. – N.A.
Hypertonia – N.A. – N.A. – N.A. 2 N.A.
Syncope – N.A. 2 N.A. – N.A. – N.A.
Angina pectoris – N.A. 2 N.A. – N.A. – N.A.
Pruritis 4 N.A. – N.A. – N.A. – N.A.
Adverse events are possibly, probably, or deﬁnitely related to stimulation based on the observed cases.
Values given in the table are percentages.
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future VNS protocols in a controlled way, as VNS
is studied as an add-on to existing antidepressant
medication. In addition, it might be argued that be-
cause VNS is an invasive procedure involving surgical
intervention, implantation of a device and repetitive
slight discomfort and voice alteration (30 s of stimu-
lation every 5 min), it is associated with an even
greater placebo response than those detected in drug
trials. In future trials of VNS for depression, it might
therefore be valuable to study the speciﬁc character-
istics of personality of a patient population with
treatment resistance interested in this procedure to
judge whether personality features contribute diﬀer-
entially to treatment eﬀects. Although we have no
general indication in the patients studied in the D03
trial, it might well be that these patients have a higher
degree of axis 2 co-morbidity, possibly conferring a
diﬀerent placebo response.
However, there are some factors that make it un-
likely that the observed antidepressant response in
this study can be attributed to placebo eﬀects
alone. First, the patients studied all suﬀered from
severe TRD, and such patients are known to be less
likely to show placebo response (Schatzberg &
Kraemer, 2000). Regarding the treatment of depression
in an elderly patient group, high placebo response
rates are seen particularly with milder depression, but
more eﬀectiveness is noted with higher drug–placebo
diﬀerences in trials with more severe forms of de-
pression (Schatzberg & Kraemer, 2000 ; Lyketsos
et al. 2003).
Second, response rates in a comparable sample
of patients with severe TRD reached 5.8% after
3 months and 11.6% after 12 months of treatment as
usual, indicating a very low likelihood of sustained
treatment response despite receiving a variety of
treatments consisting of various classes of anti-
depressants with augmentation including combi-
nation strategies, psychotherapy and ECT (Dunner
et al. 2006).
Third, we demonstrated a high proportion of
sustained antidepressant response over the time of
observation (see Fig. 3). In antidepressant trials,
placebo response appears to be less stable than the
improvement attributable to drugs (Dago & Quitkin,
1995). This has been demonstrated, for example, in a
6-week placebo-controlled study; patients who had
responded were randomized either to continue on
the same dose of citalopram or to receive placebo
for a further period of 24 weeks. Patients who
switched to placebo had re-emergence of their
depressive symptoms at a signiﬁcantly higher rate
than patients maintained on citalopram (Montgomery
et al. 1993).
In summary, our results seem to point to anti-
depressant properties of VNS in a very treatment-
resistant patient population, and even if these are due
to limitations in the protocol, the putative contribution
of the placebo eﬀect cannot be assessed.
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Fig. 3. Proportion of patients meeting diﬀerent criteria for
pattern of response to vagus nerve stimulation (VNS)
therapy. The percentage of sustained responders was higher
in the D03 sample than in the D01 sample (HAMD-28,
observed cases). The percentages of patients with ﬂuctuating
response were almost equal, but the percentage of patients
never meeting criteria for response in the ﬁrst year was lower
in the D03 sample compared to the D01 sample. Early
responders (&) : response criteria ﬁrst achieved after 3 months,
continuous to 12 months. Late responders (%) : response
criteria ﬁrst achieved after 6 or 9 months and continuous to 12
months. Fluctuating responders ( ) : response criteria achieved
once/twice after 3, 6, 9 or 12 months, no continuous response.
Non-responders ( ) : no response at any key outcome point.
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